258 related articles for article (PubMed ID: 9354768)
1. Membrane CD22 defines circulating myeloma-related cells as mature or later B cells.
Perfetti V; Vignarelli MC; Bellotti V; Glennie MJ; Zorzoli I; Ubbiali P; Obici L; Massa M; Ippoliti G; Ascari E; Merlini G
Lab Invest; 1997 Oct; 77(4):333-44. PubMed ID: 9354768
[TBL] [Abstract][Full Text] [Related]
2. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
[TBL] [Abstract][Full Text] [Related]
3. Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients.
Santonocito AM; Consoli U; Bagnato S; Milone G; Palumbo GA; Di Raimondo F; Stagno F; Guglielmo P; Giustolisi R
Leuk Res; 2004 May; 28(5):469-77. PubMed ID: 15068900
[TBL] [Abstract][Full Text] [Related]
4. AL amyloidosis. Characterization of amyloidogenic cells by anti-idiotypic monoclonal antibodies.
Perfetti V; Bellotti V; Garini P; Zorzoli I; Rovati B; Marinone MG; Ippoliti G; Merlini G
Lab Invest; 1994 Dec; 71(6):853-61. PubMed ID: 7807967
[TBL] [Abstract][Full Text] [Related]
5. Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin.
Bonardi MA; Bell A; French RR; Gromo G; Hamblin T; Modena D; Tutt AL; Glennie MJ
Int J Cancer Suppl; 1992; 7():73-7. PubMed ID: 1428411
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal circulating B cells in multiple myeloma. A continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules.
Pilarski LM; Jensen GS
Hematol Oncol Clin North Am; 1992 Apr; 6(2):297-322. PubMed ID: 1533857
[TBL] [Abstract][Full Text] [Related]
7. Differential control of CD22 ligand expression on B and T lymphocytes, and enhanced expression in murine systemic lupus.
Lajaunias F; Ida A; Kikuchi S; Fossati-Jimack L; Martinez-Soria E; Moll T; Law CL; Izui S
Arthritis Rheum; 2003 Jun; 48(6):1612-21. PubMed ID: 12794829
[TBL] [Abstract][Full Text] [Related]
8. Constitutive endocytosis and degradation of CD22 by human B cells.
Shan D; Press OW
J Immunol; 1995 May; 154(9):4466-75. PubMed ID: 7722303
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
[TBL] [Abstract][Full Text] [Related]
10. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
[TBL] [Abstract][Full Text] [Related]
12. Detection of myeloma cells in the peripheral blood by flow cytometry.
Witzig TE; Kimlinger TK; Ahmann GJ; Katzmann JA; Greipp PR
Cytometry; 1996 Jun; 26(2):113-20. PubMed ID: 8817086
[TBL] [Abstract][Full Text] [Related]
13. CD22 as a target of passive immunotherapy.
Cesano A; Gayko U
Semin Oncol; 2003 Apr; 30(2):253-7. PubMed ID: 12720147
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of the B cell-restricted molecule CD22 on neonatal B lymphocytes depending upon antigen stimulation.
Viemann D; Schlenke P; Hammers HJ; Kirchner H; Kruse A
Eur J Immunol; 2000 Feb; 30(2):550-9. PubMed ID: 10671211
[TBL] [Abstract][Full Text] [Related]
15. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
[TBL] [Abstract][Full Text] [Related]
16. Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs.
Nguyen DH; Ball ED; Varki A
Exp Hematol; 2006 Jun; 34(6):728-35. PubMed ID: 16728277
[TBL] [Abstract][Full Text] [Related]
17. Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.
French RR; Penney CA; Browning AC; Stirpe F; George AJ; Glennie MJ
Br J Cancer; 1995 May; 71(5):986-94. PubMed ID: 7734325
[TBL] [Abstract][Full Text] [Related]
18. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.
Ocqueteau M; Orfao A; Almeida J; Bladé J; González M; García-Sanz R; López-Berges C; Moro MJ; Hernández J; Escribano L; Caballero D; Rozman M; San Miguel JF
Am J Pathol; 1998 Jun; 152(6):1655-65. PubMed ID: 9626070
[TBL] [Abstract][Full Text] [Related]
19. Different expression of CD3 and CD22 in leukemic cells according to whether tested in suspension or fixed on slides.
Rani S; De Oliveira MS; Catovsky D
Hematol Pathol; 1988; 2(2):73-8. PubMed ID: 2974027
[TBL] [Abstract][Full Text] [Related]
20. SLP-76 is recruited to CD22 and dephosphorylated by SHP-1, thereby regulating B cell receptor-induced c-Jun N-terminal kinase activation.
Mizuno K; Tagawa Y; Watanabe N; Ogimoto M; Yakura H
Eur J Immunol; 2005 Feb; 35(2):644-54. PubMed ID: 15668918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
